Skip to main content
SpringerLink
Log in

Minimal residual disease quantification in adult acute lymphoblastic leukemia

  • Clinical Trials Report
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Conclusions

MRD quantification during treatment identified prognostic subgroups within standard-risk adult ALL patients without conventional risk factors. Patients who are MRD-negative at two early time points have an excellent prognosis (3-year RR, 0%), and those who remain MRD-positive at week 16 have a poor prognosis (3-year RR, 94%). For these patients, MRD evaluation is a valuable tool to predict relapse and can direct important treatment decisions. Studies to determine whether interventions based on the early identification of relapse by MRD detection will have an impact on patient outcome are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Brisco J, Hughes E, Neoh SH, et al.: Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 1996, 87:5251–5256.

    PubMed  CAS  Google Scholar 

  2. Mortuza FY, Papaioannou M, Moreira IM, et al.: Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:1094–1104.

    Article  PubMed  Google Scholar 

  3. Vidriales MB, Perez JJ, Lopez-Berges MC, et al.: Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003, 101:4695–700.

    Article  PubMed  CAS  Google Scholar 

  4. Scheinberg DA MP, Weiss M. Acute Leukemias. Philadelphia: Lipincott-Raven; 2005:2404–2432.

    Google Scholar 

  5. Hoelzer D, Thiel E, Loffier H et al.: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988, 71:123–131.

    PubMed  CAS  Google Scholar 

  6. Gaynor J, Chapman D, Little C et al.: A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol 1988, 6:1014–1030.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Heather Landau MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark A. Weiss MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Landau, H., Weiss, M.A. Minimal residual disease quantification in adult acute lymphoblastic leukemia. Curr Oncol Rep 8, 323–324 (2006). https://doi.org/10.1007/s11912-006-0053-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-006-0053-1

Keywords

Search

Navigation